Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
Autor: | Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | Molecular Oncology, Vol 17, Iss 8, Pp 1581-1594 (2023) |
Druh dokumentu: | article |
ISSN: | 1878-0261 1574-7891 |
DOI: | 10.1002/1878-0261.13439 |
Popis: | The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)‐based therapy efficacy between patients with ex20ins and non‐ex20ins. Two external cohorts (TCGA, n = 21; META‐ICI, n = 30) were used for validation. In the GLCI cohort, 68.2% of patients displayed programmed death‐ligand 1 (PD‐L1) expression |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |